Novel vaccination strategies against tuberculosis

Cold Spring Harbor Perspectives in Medicine

Volumn 4, Issue 6, 2014, Pages

  Andersen, Peter ^a   Kaufmann, Stefan H E ^b  

^a STATENS SERUM INSTITUT   (Denmark)

^b MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CATIONIC SURFACTANT; CHEMOKINE RECEPTOR CCR7; CULTURE FILTRATE PROTEIN 10; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; L SELECTIN; LIPOSOME; LIVE VACCINE; NATURAL KILLER CELL LECTIN LIKE RECEPTOR; NATURAL KILLER CELL LECTIN LIKE RECEPTOR G1; SUBUNIT VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS VECTOR; VITAMIN D;

ARTICLE; BCG VACCINATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG EFFICACY; DRUG RESEARCH; EFFECTOR CELL; FLOW CYTOMETRY; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; MACROPHAGE; MEMORY T LYMPHOCYTE; MONONUCLEAR PHAGOCYTE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; TH1 CELL; TH17 CELL; TUBERCULOSIS; VACCINIA VIRUS; IMMUNOLOGY;

BCG VACCINE; HUMANS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84920162614     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a018523     Document Type: Article

References (139)

1. Aagaard C, Hoang TT, Izzo A, Billeskov R, Troudt J, Arnett K, Keyser A, Elvang T, Andersen P, Dietrich J. 2009. Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose. PLoS ONE 4: e5930.
2. Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, Dolganov G, Schoolnik GK, Cassidy JP, Billeskov R, Andersen P. 2011. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 17: 189-194.
3. Abel B, Tameris M, Mansoor N, Gelderbloem S, Hughes J, Abrahams D, Makhethe L, Erasmus M, deKock M, vanderMerwe L, et al. 2010. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4þ and CD8þ T cells in adults. Am J Respir Crit Care Med 181: 1407-1417.
4. Abu-Raddad LJ, Sabatelli L, Achterberg JT, Sugimoto JD, Longini IM Jr, Dye C, Halloran ME. 2009. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci 106: 13980-13985.
5. Amulic B, Cazalet C, Hayes GL, Metzler KD, Zychlinsky A. 2012. Neutrophil function: From mechanisms to disease. Annu Rev Immunol 30: 459-489.
6. Andersen P. 1994. The T cell response to secreted antigens of Mycobacterium tuberculosis. Immunobiology 191: 537-547.
7. Andersen P. 2007. Vaccine strategies against latent tuberculosis infection. Trends Microbiol 15: 7-13.
8. Andersen P, Doherty TM. 2005. The success and failure of BCG—Implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3: 656-662.
9. Andersen P, Heron I. 1993. Specificity of a protective memory immune response against Mycobacterium tuberculosis. Infect Immun 61: 844-851.
10. Andersen P, Smedegaard B. 2000. CD4þ T-cell subsets that mediate immunological memory to Mycobacterium tuberculosis infection in mice. Infect Immun 68: 621-629.
11. Andersen P, Doherty TM, Pai M, Weldingh K. 2007. The prognosis of latent tuberculosis: Can disease be predicted? Trends Mol Med 13: 175-182.
12. Arbues A, Aguilo JI, Gonzalo-Asensio J, Marinova D, Uranga S, Puentes E, Fernandez C, Parra A, Cardona PJ, Vilaplana C, et al. 2013. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine 31: 4867-4873.
13. Barry CE 3rd, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D. 2009. The spectrum of latent tuberculosis: Rethinking the biology and intervention strategies. Nat Rev Microbiol 7: 845-855.
14. Behr MA, Wilson MA, Gill WP, Salamon H, Schoolnik GK, Rane S, Small PM. 1999. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284: 1520-1523.
15. Benn CS, Netea MG, Selin LK, Aaby P. 2013. A small jab—A big effect: Nonspecific immunomodulation by vaccines. Trends Immunol 34: 431-439.
16. Bennekov T, Dietrich J, Rosenkrands I, Stryhn A, Doherty TM, Andersen P. 2006. Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis. Eur J Immunol 36: 3346-3355.
17. Bermudez LE, Young LS. 1990. Recombinant granulocyte— Macrophage colony-stimulating factor activates human macrophages to inhibit growth or kill Mycobacterium avium complex. J Leukoc Biol 48: 67-73.
18. Bertholet S, Ireton GC, Ordway DJ, Windish HP, Pine SO, Kahn M, Phan T, Orme IM, Vedvick TS, Baldwin SL, et al. 2010. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med 2: 53ra74.
19. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. 2002. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 43: 717-731.
20. Beveridge NE, Price DA, Casazza JP, Pathan AA, Sander CR, Asher TE, Ambrozak DR, Precopio ML, Scheinberg P, Alder NC, et al. 2007. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4þ memory T lymphocyte populations. Eur J Immunol 37: 3089-3100.
21. Beverley P. 2013. TB vaccine failure was predictable. Nature 503: 469.
22. Billeskov R, Elvang TT, Andersen PL, Dietrich J. 2012. The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity. PLoS ONE 7: e39909.
23. Billeskov R, Christensen JP, Aagaard C, Andersen P, Dietrich J. 2013. Comparing adjuvanted H28 and modified vaccinia virus ankara expressing H28 in a mouse and a nonhuman primate tuberculosis model. PLoS ONE 8: e72185.
24. Biselli R, Mariotti S, Sargentini V, Sauzullo I, Lastilla M, Mengoni F, Vanini V, Girardi E, Goletti D, D’Amelio R, et al. 2010. Detection of interleukin-2 in addition to interferon-g discriminates active tuberculosis patients, latently infected individuals, and controls. Clin Microbiol Infect 16: 1282-1284.
25. Bold TD, Banaei N, Wolf AJ, Ernst JD. 2011. Suboptimal activation of antigen-specific CD4þ effector cells enables persistence of M. tuberculosis in vivo. PLoS Pathog 7: e1002063.
26. Bonneville M, Scotet E. 2006. Human Vg9Vd2 T cells: Promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol 18: 539-546.
27. Brigl M, Brenner MB. 2004. CD1: Antigen presentation and T cell function. Annu Rev Immunol 22: 817-890.
28. Bustamante J, Picard C, Boisson-Dupuis S, Abel L, Casanova JL. 2011. Genetic lessons learned from X-linked Mendelian susceptibility to mycobacterial diseases. Ann NY Acad Sci 1246: 92-101.
29. Calmette A, Plotz H. 1929. Protective inoculation against tuberculosis with BCG. Am Rev Tuberc 19: 567-572.
30. Calmette A, Guérin C, Boquet A, Négre L. 1927. La vaccination préventive contre la tuberculose par le “BCG”. Masson, Paris.
31. Cardona PJ. 2006. RUTI: A new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinburgh) 86: 273-289.
32. Coler RN, Bertholet S, Pine SO, Orr MT, Reese V, Windish HP, Davis C, Kahn M, Baldwin SL, Reed SG. 2013. Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. J Infect Dis 207: 1242-1252.
33. Collins HL, Kaufmann SH. 2001. Prospects for better tuberculosis vaccines. Lancet Infect Dis 1: 21-28.
34. Commandeur S, vanMeijgaarden KE, Lin MY, Franken KL, Friggen AH, Drijfhout JW, Oftung F, Korsvold GE, Geluk A, Ottenhoff TH. 2011. Identification of human T-cell responses to Mycobacterium tuberculosis resuscitationpromoting factors in long-term latently infected individuals. Clin Vaccine Immunol 18: 676-683.
35. Commandeur S, vanMeijgaarden KE, Prins C, Pichugin AV, Dijkman K, vandenEeden SJ, Friggen AH, Franken KL, Dolganov G, Kramnik I, Sphoolnik GK, et al. 2013. An unbiased genome-wide Mycobacterium tuberculosis gene expression approach to discover antigens targeted by human T cells expressed during pulmonary infection. J Immunol 190: 1659-1671.
36. Cooper AM, Torrado E. 2012. Protection versus pathology in tuberculosis: Recent insights. Curr Opin Immunol 24: 431-437.
37. Cruz A, Fraga AG, Fountain JJ, Rangel-Moreno J, Torrado E, Saraiva M, Pereira DR, Randall TD, Pedrosa J, Cooper AM, et al. 2010. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J Exp Med 207: 1609-1616.
38. Darrah PA, Patel DT, DeLuca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL, et al. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13: 843-850.
39. Day CL, Tameris M, Mansoor N, vanRooyen M, deKock M, Geldenhuys H, Erasmus M, Makhethe L, Hughes EJ, Gelderbloem S, et al. 2013. Induction and regulation of Tcell immunity by the novel tuberculosis vaccine M72/ AS01 in South African adults. Am J Respir Crit Care Med 188: 492-502.
40. deBruyn G, Garner P. 2010. Mycobacterium vaccae immunotherapy for treating tuberculosis. The Cochrane Library 1: 1-17.
41. Decatur AL, Portnoy DA. 2000. A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity. Science 290: 992-995.
42. Demissie A, Leyten EM, Abebe M, Wassie L, Aseffa A, Abate G, Fletcher H, Owiafe P, Hill PC, Brookes R, et al. 2006. Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol 13: 179-186.
43. Derrick SC, Perera LP, Dheenadhayalan V, Yang A, Kolibab K, Morris SL. 2008. The safety of post-exposure vaccination of mice infected with Mycobacterium tuberculosis. Vaccine 26: 6092-6098.
44. Derrick SC, Yabe IM, Yang A, Morris SL. 2011. Vaccineinduced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells. Vaccine 29: 2902-2909.
45. Desel C, Werninghaus K, Ritter M, Jozefowski K, Wenzel J, Russkamp N, Schleicher U, Christensen D, Wirtz S, Kirschning C, et al. 2013. The Mincle-activating adjuvant TDB induces MyD88-dependent Th1 and Th17 responses through IL-1R signaling. PLoS ONE 8: e53531.
46. Dietrich J, Aagaard C, Leah R, Olsen AW, Stryhn A, Doherty TM, Andersen P. 2005. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: Efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 174: 6332-6339.
47. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, Symmons DP. 2010. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69: 522-528.
48. Doherty TM, Andersen P. 2005. Vaccines for tuberculosis: Novel concepts and recent progress. Clin Microbiol Rev 18: 687-702.
49. Elias D, Akuffo H, Britton S. 2005. PPD induced in vitro interferon g production is not a reliable correlate of protection against Mycobacterium tuberculosis. Trans R Soc Trop Med Hyg 99: 363-368.
50. Elvang T, Christensen JP, Billeskov R, Thi Kim Thanh Hoang T, Holst P, Thomsen AR, Andersen P, Dietrich J. 2009. CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination. PLoS ONE 4: e5139.
51. Ernst JD. 2012. The immunological life cycle of tuberculosis. Nat Rev Immunol 12: 581-591.
52. Fabri M, Stenger S, Shin DM, Yuk JM, Liu PT, Realegeno S, Lee HM, Krutzik SR, Schenk M, Sieling PA, et al. 2011. Vitamin D is required for IFN-g-mediated antimicrobial activity of human macrophages. Sci Transl Med 3: 104ra102.
53. Forbes EK, Sander C, Ronan EO, McShane H, Hill AV, Beverley PC, Tchilian EZ. 2008. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 181: 4955-4964.
54. Frick M. 2013. Where are we going, where have we been? In The HIV, HCV, TB pipeline report, pp. 263-283.http:// www.pipelinereport.org.
55. Gengenbacher M, Kaufmann SH. 2012. Mycobacterium tuberculosis: Success through dormancy. FEMS Microbiol Rev 36: 514-532.
56. Goldsack L, Kirman JR. 2007. Half-truths and selective memory: Interferon g, CD4þ T cells and protective memory against tuberculosis. Tuberculosis (Edinburgh) 87: 465-473.
57. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AV. 2003. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 171: 1602-1609.
58. Govender L, Abel B, Hughes EJ, Scriba TJ, Kagina BM, deKock M, Walzl G, Black G, Rosenkrands I, Hussey GD, et al. 2010. Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease. Vaccine 29: 51-57.
59. Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, NasserEddine A, Mann P, Goosmann C, Bandermann S, Smith D, et al. 2005. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J Clin Invest 115: 2472-2479.
60. Grode L, Ganoza CA, Brohm C, Weiner J III, Eisele B, Kaufmann SH. 2013. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 openlabel randomized clinical trial. Vaccine 31: 1340-1348.
61. Gupta RK, Srivastava BS, Srivastava R. 2010. Comparative expression analysis of rpf-like genes of Mycobacterium tuberculosis H37Rv under different physiological stress and growth conditions. Microbiology 156: 2714-2722.
62. Gupta A, Ahmad FJ, Ahmad F, Gupta UD, Natarajan M, Katoch V, Bhaskar S. 2012a. Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung. PLoS ONE 7: e39215.
63. Gupta A, Ahmad FJ, Ahmad F, Gupta UD, Natarajan M, Katoch VM, Bhaskar S. 2012b. Protective efficacy of Mycobacterium indicus pranii against tuberculosis and underlying local lung immune responses in guinea pig model. Vaccine 30: 6198-6209.
64. Guttstadt A. 1891. Die Wirksamkeit des Koch’schen Heilmittels gegen Tuberculose. Springer, Berlin (in German).
65. Hatherill M. 2011. Prospects for elimination of childhood tuberculosis: The role of new vaccines. Arch Dis Child 96: 851-856.
66. Henao-Tamayo M, Palaniswamy GS, Smith EE, Shanley CA, Wang B, Orme IM, Basaraba RJ, DuTeau NM, Ordway D. 2009. Post-exposure vaccination against Mycobacterium tuberculosis. Tuberculosis (Edinburgh) 89: 142-148.
67. Hesseling AC, Schaaf HS, Victor T, Beyers N, Marais BJ, Cotton MF, Wiid I, Gie RP, van Helden P, Warren RM. 2004. Resistant Mycobacterium bovis bacillus Calmette-Guérin disease: Implications for management of bacillus Calmette-Guérin disease in human immunodeficiency virus-infected children. Pediatr Infect Dis J 23: 476-479.
68. Hoang T, Aagaard C, Dietrich J, Cassidy JP, Dolganov G, Schoolnik GK, Lundberg CV, Agger EM, Andersen P. 2013. ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for preand post-exposure tuberculosis vaccination. PLoS ONE 8: e80579.
69. Houghton J, Cortes T, Schubert O, Rose G, Rodgers A, De Ste Croix M, Aebersold R, Young DB, Arnvig KB. 2013. A small RNA encoded in the Rv2660c locus of Mycobacterium tuberculosis is induced during starvation and infection. PLoS ONE 8: e80047.
70. Janaszek W. 1991. Evaluation of thermostability of lyophilized BCG vaccines by using an accelerated thermal degradation test. Med Dosw Mikrobiol 43: 43-49.
71. Jeon BY, Kim SC, Eum SY, Cho SN. 2011. The immunity and protective effects of antigen 85A and heat-shock protein X against progressive tuberculosis. Microbes Infect 13: 284-290.
72. Joshi NS, Cui W, Chandele A, Lee HK, Urso DR, Hagman J, Gapin L, Kaech SM. 2007. Inflammation directs memory precursor and short-lived effector CD8þ T cell fates via the graded expression of T-bet transcription factor. Immunity 27: 281-295.
73. Kagina BM, Abel B, Scriba TJ, Hughes EJ, Keyser A, Soares A, Gamieldien H, Sidibana M, Hatherill M, Gelderbloem S, et al. 2010. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. Am J Respir Crit Care Med 182: 1073-1079.
74. Kamath AT, Rochat AF, Christensen D, Agger EM, Andersen P, Lambert PH, Siegrist CA. 2009. A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells. PLoS ONE 4: e5771.
75. Kaufmann SHE. 2010. The new plagues—Pandemics and poverty in a globalized world. Haus Publishing Limited, London. Kaufmann SH. 2011. Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect Dis 11: 633-640.
76. Kaufmann SH. 2012. Tuberculosis vaccine development: Strength lies in tenacity. Trends Immunol 33: 373-379.
77. Kaufmann SH. 2013. Tuberculosis vaccines: Time to think about the next generation. Semin Immunol 25: 172-181.
78. Kaufmann SH, Dorhoi A. 2013. Inflammation in tuberculosis: Interactions, imbalances and interventions. Curr Opin Immunol 25: 441-449.
79. Kaufmann SH, Winau F. 2005. From bacteriology to immunology: The dualism of specificity. Nat Immunol 6: 1063-1066.
80. Kaufmann SH, Hussey G, Lambert PH. 2010. New vaccines for tuberculosis. Lancet 375: 2110-2119.
81. Kaufmann SH, Cotton MF, Eisele B, Gengenbacher M, Grode L, Hesseling AC, Waltzl G. 2014. The BCG replacement vaccine VPM1002: From drawing board to clinical trail. Expert Rev Vaccines 13: 619-630.
82. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. 2001. Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent. N Engl J Med 345: 1098-1104.
83. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, Shen F, Eaton SM, Gaffen SL, Swain SL, et al. 2007. IL-23 and IL-17 in the establishment of protective pulmonary CD4þ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8: 369-377.
84. Knudsen NP, Norskov-Lauritsen S, Dolganov GM, Schoolnik GK, Lindenstrom T, Andersen P, Agger EM, Aagaard C. 2014. Tuberculosis vaccine with high predicted population coverage and compatibility with modern diagnostics. Proc Natl Acad Sci 111: 1096-1101.
85. Kupferschmidt K. 2011. Infectious disease. Taking a new shot at a TB vaccine. Science 334: 1488-1490.
86. Leroux-Roels I, Forgus S, DeBoever F, Clement F, Demoitie MA, Mettens P, Moris P, Ledent E, Leroux-Roels G, OforiAnyinam O, et al. 2013. Improved CD4þ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/ AS02 tuberculosis candidate vaccine formulations: A randomized trial. Vaccine 31: 2196-2206.
87. Leyten EM, Lin MY, Franken KL, Friggen AH, Prins C, van Meijgaarden KE, Voskuil MI, Weldingh K, Andersen P, Schoolnik GK, et al. 2006. Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect 8: 2052-2060.
88. Lin PL, Dietrich J, Tan E, Abalos RM, Burgos J, Bigbee C, Bigbee M, Milk L, Gideon HP, Rodgers M, et al. 2012. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J Clin Invest 122: 303-314.
89. Lindenstrom T, Agger EM, Korsholm KS, Darrah PA, Aagaard C, Seder RA, Rosenkrands I, Andersen P. 2009. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 182: 8047-8055.
90. Lindenstrom T, Woodworth J, Dietrich J, Aagaard C, Andersen P, Agger EM. 2012. Vaccine-induced Th17 cells are maintained long-term postvaccination as a distinct and phenotypically stable memory subset. Infect Immun 80: 3533-3544.
91. Lindenstrom T, Knudsen NP, Agger EM, Andersen P. 2013. Control of chronic mycobacterium tuberculosis infection by CD4 KLRG1IL-2-secreting central memory cells. J Immunol 190: 6311-6319.
92. Lingnau K, Riedl K, von Gabain A. 2007. IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems. Expert Rev Vaccines 6: 741-746.
93. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, et al. 2006. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311: 1770-1773.
94. MacMicking J, Xie QW, Nathan C. 1997. Nitric oxide and macrophage function. Annu Rev Immunol 15: 323-350.
95. Maertzdorf J, Weiner J III, Kaufmann SH. 2012. Enabling biomarkers for tuberculosis control. Int J Tuberc Lung Dis 16: 1140-1148.
96. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, Fletcher HA, Hill AV. 2004. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10: 1240-1244.
97. Mittrucker HW, Steinhoff U, Kohler A, Krause M, Lazar D, Mex P, Miekley D, Kaufmann SH. 2007. Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. Proc Natl Acad Sci 104: 12434-12439.
98. Mollenkopf HJ, Kursar M, Kaufmann SH. 2004. Immune response to postprimary tuberculosis in mice: Mycobacterium tuberculosis and Mycobacterium bovis bacille Calmette-Guérin induce equal protection. J Infect Dis 190: 588-597.
99. News in Brief. 2007. HIV vaccine failure prompts Merck to halt trial. Nature 449: 390.
100. O’Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. 2013. The immune response in tuberculosis. Annu Rev Immunol 31: 475-527.
101. Orme IM. 1988. Characteristics and specificity of acquired immunologic memory to Mycobacterium tuberculosis infection. J Immunol 140: 3589-3593.
102. Orme IM. 2010. The Achilles heel of BCG. Tuberculosis (Edinburgh) 90: 329-332.
103. Orme IM, Collins FM. 1984. Adoptive protection of the Mycobacterium tuberculosis-infected lung. Dissociation between cells that passively transfer protective immunity and those that transfer delayed-type hypersensitivity to tuberculin. Cell Immunol 84: 113-120.
104. Ottenhoff TH. 2012. New pathways of protective and pathological host defense to mycobacteria. Trends Microbiol 20: 419-428.
105. Palmer M. 2001. The family of thiol-activated, cholesterolbinding cytolysins. Toxicon 39: 1681-1689.
106. Park HD, Guinn KM, Harrell MI, Liao R, Voskuil MI, Tompa M, Schoolnik GK, Sherman DR. 2003. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microbiol 48: 833-843.
107. Prabowo SA, Groschel MI, Schmidt ED, Skrahina A, Mihaescu T, Hasturk S, Mitrofanov R, Pimkina E, Visontai I, deJong B, et al. 2013. Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines. Med Microbiol Immunol 202: 95-104.
108. Radosevic K, Wieland CW, Rodriguez A, Weverling GJ, Mintardjo R, Gillissen G, Vogels R, Skeiky YA, Hone DM, Sadoff JC, et al. 2007. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of g interferon. Infect Immun 75: 4105-4115.
109. Reece ST, Kaufmann SH. 2012. Floating between the poles of pathology and protection: Can we pin down the granuloma in tuberculosis? Curr Opin Microbiol 15: 63-70.
110. Reed SG, Coler RN, Dalemans W, Tan EV, DeLaCruz EC, Basaraba RJ, Orme IM, Skeiky YA, Alderson MR, Cowgill KD, et al. 2009. Defined tuberculosis vaccine, Mtb72F/ AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci 106: 2301-2306.
111. Reiley WW, Shafiani S, Wittmer ST, Tucker-Heard G, Moon JJ, Jenkins MK, Urdahl KB, Winslow GM, Woodland DL. 2010. Distinct functions of antigen-specific CD4 T cells during murine Mycobacterium tuberculosis infection. Proc Natl Acad Sci 107: 19408-19413.
112. Rohde K, Yates RM, Purdy GE, Russell DG. 2007. Mycobacterium tuberculosis and the environment within the phagosome. Immunol Rev 219: 37-54.
113. Roth A, Garly ML, Jensen H, Nielsen J, Aaby P. 2006. Bacillus Calmette-Guérin vaccination and infant mortality. Expert Rev Vaccines 5: 277-293.
114. Rustad TR, Harrell MI, Liao R, Sherman DR. 2008. The enduring hypoxic response of Mycobacterium tuberculosis. PLoS ONE 3: e1502.
115. Sallusto F, Geginat J, Lanzavecchia A. 2004. Central memory and effector memory T cell subsets: Function, generation, and maintenance. Annu Rev Immunol 22: 745-763.
116. Schuck SD, Mueller H, Kunitz F, Neher A, Hoffmann H, Franken KL, Repsilber D, Ottenhoff TH, Kaufmann SH, Jacobsen M. 2009. Identification of T-cell antigens specific for latent Mycobacterium tuberculosis infection. PLoS ONE 4: e5590.
117. Scriba TJ, Tameris M, Smit E, van der Merwe L, Hughes EJ, Kadira B, Mauff K, Brittain N, Lawrie A, Mulenga H, et al. 2012. A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV-and/or Mycobacterium tuberculosis-infected adults. Am J Respir Crit Care Med 185: 769-778.
118. Seder RA, Darrah PA, Roederer M. 2008. T-cell quality in memory and protection: Implications for vaccine design. Nat Rev Immunol 8: 247-258.
119. Shi L, North R, Gennaro ML. 2004. Effect of growth state on transcription levels of genes encoding major secreted antigens of Mycobacterium tuberculosis in the mouse lung. Infect Immun 72: 2420-2424.
120. Smaill F, Jeyanathan M, Smieja M, Medina MF, Thanthrige-Don N, Zganiacz A, Yin C, Heriazon A, Damjanovic D, Puri L, et al. 2013. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl Med 5: 205ra134.
121. Soares AP, KwongChung CK, Choice T, Hughes EJ, Jacobs G, van Rensburg EJ, Khomba G, deKock M, Lerumo L, Makhethe L, et al. 2013. Longitudinal changes in CD4þ T-cell memory responses induced by BCG vaccination of newborns. J Infect Dis 207: 1084-1094.
122. Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, Ganz T, Thoma-Uszynski S, Melian A, Bogdan C, et al. 1998. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 282: 121-125.
123. StopTBPartnership, WHO. 2011. The global plan to stop TB 2011-2015.
124. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, et al. 2013. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised, placebo-controlled phase 2b trial. Lancet 381: 1021-1028.
125. Tolderlund K. 1952. Preliminary report of laboratory investigations on the effect of light on BCG vaccine. Acta Pathol Microbiol Scand Suppl 93: 299-307.
126. UNAIDS, WHO. 2013. Global Report: UNAIDS report on the global AIDS epidemic 2013. WHO, Geneva.
127. van Dissel JT, Arend SM, Prins C, Bang P, Tingskov PN, Lingnau K, Nouta J, Klein MR, Rosenkrands I, Ottenhoff TH, et al. 2010. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine 28: 3571-3581.
128. Verreck FA, Vervenne RA, Kondova I, van Kralingen KW, Remarque EJ, Braskamp G, van der Werff NM, Kersbergen A, Ottenhoff TH, Heidt PJ, et al. 2009. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS ONE 4: e5264.
129. von Reyn CF, Mtei L, Arbeit RD, Waddell R, Cole B, Mackenzie T, Matee M, Bakari M, Tvaroha S, Adams LV, et al. 2010. Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 24: 675-685.
130. Walker KB, Brennan MJ, Ho MM, Eskola J, Thiry G, Sadoff J, Dobbelaer R, Grode L, Liu MA, Fruth U, et al. 2010. The second Geneva Consensus: Recommendations for novel live TB vaccines. Vaccine 28: 2259-2270.
131. Wang J, Thorson L, Stokes RW, Santosuosso M, Huygen K, Zganiacz A, Hitt M, Xing Z. 2004. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 173: 6357-6365.
132. Weiner J, Kaufmann SHE. 2014. Recent advances towards tuberculosis control: Vaccines and biomarkers. J Intern Med 275: 467-480.
133. Weiner J, Maertzdorf J, Kaufmann SH. 2013. The dual role of biomarkers for understanding basic principles and devising novel intervention strategies in tuberculosis. Ann NY Acad Sci 1283: 22-29.
134. Weinrich Olsen A, van Pinxteren LA, Meng Okkels L, Birk Rasmussen P, Andersen P. 2001. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Infect Immun 69: 2773-2778.
135. White AD, Sibley L, Dennis MJ, Gooch K, Betts G, Edwards N, Reyes-Sandoval A, Carroll MW, Williams A, Marsh PD, et al. 2013. Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques. Clin Vaccine Immunol 20: 663-672.
136. WHO. 2013. Global tuberculosis report 2013. WHO, Geneva.
137. Woodworth JS, Behar SM. 2006. Mycobacterium tuberculosis-specific CD8þ T cells and their role in immunity. Crit Rev Immunol 26: 317-352.
138. Yang XY, Chen QF, Li YP, Wu SM. 2011. Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: A metaanalysis. PLoS ONE 6: e23826.
139. Zheng J, Liu L, Wei C, Leng W, Yang J, Li W, Wang J, Jin Q. 2012. A comprehensive proteomic analysis of Mycobacterium bovis bacillus Calmette-Guérin using high resolution Fourier transform mass spectrometry. J Proteomics 77: 357-371.